FDA approves Genentech′s bispecific antibody for lymphoma

被引：3

作者：

Carvalho, Thiago

机构：

来源：

NATURE MEDICINE | 2023年 / 29卷 / 03期

关键词：

D O I：

10.1038/d41591-023-00010-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

引用

页码：507 / 508

页数：2

共 50 条

[1] FDA approves Genentech’s bispecific antibody for lymphoma
Thiago Carvalho
[J]. Nature Medicine, 2023, 29 : 507 - 508
[2] FDA approves bispecific antibody for two eye diseases
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2022, 21 : 170 - 170
[3] FDA approves bispecific antibody for two eye diseases
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) : 170 - 170
[4] FDA approves first bispecific
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2015, 14 : 7 - 7
[5] FDA approves first bispecific
不详
[J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (01) : 7 - 7
[6] FDA approves Genentech's cathfloactivase for use in occluded pediatric CVADs
Herman, JG
[J]. DIALYSIS & TRANSPLANTATION, 2005, 34 (03) : 126 - 126
[7] FDA approves antitoxin antibody
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (12) : 811 - 811
[8] FDA approves antitoxin antibody
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2016, 15 : 811 - 811
[9] FDA approves first-in-class bispecific for multiple myeloma
[J]. Nature Biotechnology, 2023, 41 : 1180 - 1180
[10] FDA approves first-in-class bispecific for multiple myeloma
不详
[J]. NATURE BIOTECHNOLOGY, 2023, 41 (09) : 1181 - 1181

← 1 2 3 4 5 →